Company: DecideAct A/S

Website: www.spermosens.com

Transaction type: Rights Issue

Date: November 2022

Amount: 24 mSEK

Description of company:

Spermosen’s goal is to improve male fertility diagnosis and treatment through the introduction of breakthrough products. Spermosen’s first patented product JUNO-Checked measures the binding capacity between sperm and egg cell, which is a prerequisite for natural fertilisation. The results are expected to help physicians choose the appropriate treatment method, contributing to more successful IVF treatments, reduced suffering and improved quality of life. The WHO estimates that more than 48 million couples are affected by infertility, half of which are wholly or partly caused by a male factor.

Press Release:

https://news.cision.com/se/spermosens/r/spermosens-foreslar-foretradesemission-pa-24-msek-med-sikte-pa-produktion-och-marknadslansering,c3667703

https://news.cision.com/decideact/r/decideact-receives-an-additional-investment-of-dkk-6-5-million-from-its-largest-shareholder–the-inv,c3613835